Propanc Biopharma, Inc. (PPCB) — SEC Filings
Propanc Biopharma, Inc. (PPCB) — 45 SEC filings. Latest: EFFECT (Apr 21, 2026). Includes 27 8-K, 6 10-Q, 6 S-1/A.
View Propanc Biopharma, Inc. on SEC EDGAR
Overview
Propanc Biopharma, Inc. (PPCB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 30, 2025: Propanc Biopharma, Inc. (PPCB), a development-stage healthcare company focused on cancer treatments, filed an S-1 to register 2,000,000 shares of common stock for resale by Hexstone Capital LLC. This registration stems from a Securities Purchase Agreement on October 7, 2025, which closed on November
Sentiment Summary
Across 45 filings, the sentiment breakdown is: 4 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Propanc Biopharma, Inc. is neutral.
Filing Type Overview
Propanc Biopharma, Inc. (PPCB) has filed 1 EFFECT, 2 S-1, 6 10-Q, 27 8-K, 2 10-K, 6 S-1/A, 1 8-K/A with the SEC between Feb 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (45)
Risk Profile
Risk Assessment: Of PPCB's 44 recent filings, 5 were flagged as high-risk, 37 as medium-risk, and 2 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$4,837,738 |
| EPS | -$0.39 |
| Debt-to-Equity | 0.20 |
| Cash Position | $602,737 |
| Operating Margin | N/A |
| Total Assets | $17,975,681 |
| Total Debt | $1,179,179 |
Key Executives
- James Nathanielsz
- Julian Kenyon
- 61-03-9882-0780
Industry Context
Propanc Biopharma operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on oncology. The industry is characterized by long development cycles, significant research and development costs, and stringent regulatory hurdles. Success hinges on groundbreaking scientific innovation, successful clinical trials, and securing substantial funding to navigate these challenges.
Top Tags
equity-sale (21) · financial-obligation (19) · material-agreement (17) · material-definitive-agreement (8) · 10-Q (5) · sec-filing (5) · pharmaceutical (5) · Biopharma (4) · financials (4) · debt (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Gross proceeds from initial closing | $1.0M | Received from Hexstone Capital LLC for Series C Preferred Stock |
| Potential gross proceeds from warrant exercise | $99.0M | If the warrant for 9,900 Series C Preferred Stock is fully exercised at $10,000 per share |
| Shares of Common Stock registered for resale | 2,000,000 | Issuable upon conversion of Series C Preferred Stock held by Selling Stockholder |
| Common Stock price | $0.7498 | Last reported sale price on Nasdaq as of December 15, 2025 |
| Initial Series C Preferred Stock shares | 100 | Issued to Hexstone Capital LLC |
| Series C Preferred Stock shares | 9,900 | Issuable upon exercise of the Warrant held by Hexstone Capital LLC |
| Beneficial ownership limitation | 4.99% | Initial conversion limitation for Series C Preferred Stock, adjustable to 9.99% |
| Required Reserve Amount | 9,500,000 | Initial number of Common Stock shares reserved for Series C Preferred Stock conversion |
| Net Loss | $4,837,738 | for three months ended September 30, 2025, up from $354,310 in 2024 |
| Administration Expenses | $4,598,574 | for three months ended September 30, 2025, up from $220,759 in 2024 |
| Cash | $602,737 | as of September 30, 2025, up from $12,088 at June 30, 2025 |
| Proceeds from Sale of Common Stock | $3,314,458 | for three months ended September 30, 2025 |
| Total Assets | $17,975,681 | as of September 30, 2025, down from $19,631,808 at June 30, 2025 |
| Total Liabilities | $3,614,514 | as of September 30, 2025, down from $5,725,616 at June 30, 2025 |
| Common Stock Shares Outstanding | 12,806,748 | as of September 30, 2025, up from 11,611,782 at June 30, 2025 |
Frequently Asked Questions
What are the latest SEC filings for Propanc Biopharma, Inc. (PPCB)?
Propanc Biopharma, Inc. has 45 recent SEC filings from Feb 2024 to Apr 2026, including 27 8-K, 6 10-Q, 6 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PPCB filings?
Across 45 filings, the sentiment breakdown is: 4 bearish, 40 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Propanc Biopharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Propanc Biopharma, Inc. (PPCB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Propanc Biopharma, Inc.?
Key financial highlights from Propanc Biopharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PPCB?
The investment thesis for PPCB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Propanc Biopharma, Inc.?
Key executives identified across Propanc Biopharma, Inc.'s filings include James Nathanielsz, Julian Kenyon, 61-03-9882-0780.
What are the main risk factors for Propanc Biopharma, Inc. stock?
Of PPCB's 44 assessed filings, 5 were flagged high-risk, 37 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from Propanc Biopharma, Inc.?
Forward guidance and predictions for Propanc Biopharma, Inc. are extracted from SEC filings as they are enriched.